Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Repatha (evolocumab by Year
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M)
Amgen Repatha (evolocumab: $3,016M in FY2025, up 35.7% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,016 | +35.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 2,222 | +35.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,635 | +26.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 1,296 | +16.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,117 | +25.9% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 887 | +34.2% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 661 | +20.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 550 | +72.4% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 319 | +126.2% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 141 | +1,310.0% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 10 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up repatha (evolocumab
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M)1,663 · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Rest of World (ROW) product sales ($M)1,353 · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide reported sales growth YoY (%)36.0% · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%)43.0% · FY2024
Cite this data
StockData. (2026). Amgen Repatha (evolocumab ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-repatha-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.